0 15 Glucocorticoids glucocorticoid NNS 16 23 promote promote VBP 24 37 nonphlogistic nonphlogistic JJ 38 50 phagocytosis phagocytosis NN 51 53 of of IN 54 63 apoptotic apoptotic JJ 64 74 leukocytes leukocyte NNS 74 75 . . . 77 86 Phagocyte Phagocyte NNP 87 98 recognition recognition NN 98 99 , , , 100 106 uptake uptake NN 106 107 , , , 108 111 and and CC 112 125 nonphlogistic nonphlogistic JJ 126 137 degradation degradation NN 138 140 of of IN 141 152 neutrophils neutrophil NNS 153 156 and and CC 157 162 other other JJ 163 173 leukocytes leukocyte NNS 174 184 undergoing undergo VBG 185 194 apoptosis apoptosis NN 195 202 promote promote VBP 203 206 the the DT 207 217 resolution resolution NN 218 220 of of IN 221 233 inflammation inflammation NN 233 234 . . . 235 239 This this DT 240 245 study study NN 246 254 assessed assess VBD 255 258 the the DT 259 266 effects effect NNS 267 269 of of IN 270 287 anti-inflammatory anti-inflammatory JJ 288 303 glucocorticoids glucocorticoid NNS 304 306 on on IN 307 311 this this DT 312 321 leukocyte leukocyte NN 322 331 clearance clearance NN 332 341 mechanism mechanism NN 341 342 . . . 343 355 Pretreatment Pretreatment NNP 356 358 of of IN 359 360 “ `` `` 360 370 semimature semimature JJ 370 371 ” '' '' 372 377 5-day 5-day JJ 378 383 human human JJ 384 400 monocyte-derived monocyte-derived JJ 401 412 macrophages macrophage NNS 413 414 ( ( ( 414 415 M M NNP 416 419 phi phi NN 419 420 ) ) ) 421 424 for for IN 425 427 24 24 CD 428 429 h h NN 430 434 with with IN 435 453 methylprednisolone methylprednisolone NN 453 454 , , , 455 468 dexamethasone dexamethasone NN 468 469 , , , 470 473 and and CC 474 488 hydrocortisone hydrocortisone NN 488 489 , , , 490 493 but but CC 494 497 not not RB 498 501 the the DT 502 519 nonglucocorticoid nonglucocorticoid NN 520 528 steroids steroid NNS 529 540 aldosterone aldosterone NN 540 541 , , , 542 551 estradiol estradiol NN 551 552 , , , 553 556 and and CC 557 569 progesterone progesterone NN 569 570 , , , 571 582 potentiated potentiate VBD 583 595 phagocytosis phagocytosis NN 596 598 of of IN 599 608 apoptotic apoptotic JJ 609 620 neutrophils neutrophil NNS 620 621 . . . 622 627 These these DT 628 635 effects effect NNS 636 640 were be VBD 641 649 specific specific JJ 650 652 in in IN 653 657 that that IN 658 661 the the DT 662 673 potentiated potentiated JJ 674 686 phagocytosis phagocytosis NN 687 689 of of IN 690 699 apoptotic apoptotic JJ 700 711 neutrophils neutrophil NNS 712 715 was be VBD 716 726 completely completely RB 727 734 blocked block VBN 735 737 by by IN 738 741 the the DT 742 756 glucocorticoid glucocorticoid NN 757 765 receptor receptor NN 766 776 antagonist antagonist NN 777 784 RU38486 ru38486 NN 784 785 , , , 786 789 and and CC 790 805 glucocorticoids glucocorticoid NNS 806 809 did do VBD 810 813 not not RB 814 821 promote promote VB 822 827 5-day 5-day JJ 828 829 M M NNP 830 833 phi phi NN 834 843 ingestion ingestion NN 844 846 of of IN 847 856 opsonized opsonize VBN 857 869 erythrocytes erythrocyte NNS 869 870 . . . 871 878 Similar similar JJ 879 902 glucocorticoid-mediated glucocorticoid-mediated JJ 903 915 potentiation potentiation NN 916 919 was be VBD 920 928 observed observe VBN 929 933 with with IN 934 939 5-day 5-day JJ 940 941 M M NNP 942 945 phi phi NN 946 952 uptake uptake NN 953 955 of of IN 956 967 alternative alternative JJ 968 977 apoptotic apoptotic JJ 978 979 “ `` `` 979 986 targets target NNS 986 987 ” '' '' 988 989 ( ( ( 989 1000 eosinophils eosinophil NNS 1001 1004 and and CC 1005 1011 Jurkat Jurkat NNP 1012 1013 T t NN 1014 1019 cells cell NNS 1019 1020 ) ) ) 1021 1024 and and CC 1025 1027 in in IN 1028 1034 uptake uptake NN 1035 1037 of of IN 1038 1047 apoptotic apoptotic JJ 1048 1059 neutrophils neutrophil NNS 1060 1062 by by IN 1063 1074 alternative alternative JJ 1075 1085 phagocytes phagocyte NNS 1086 1087 ( ( ( 1087 1092 human human JJ 1093 1103 glomerular glomerular JJ 1104 1113 mesangial mesangial JJ 1114 1119 cells cell NNS 1120 1123 and and CC 1124 1130 murine murine JJ 1131 1132 M M NNP 1133 1136 phi phi NN 1137 1145 elicited elicit VBD 1146 1150 into into IN 1151 1154 the the DT 1155 1165 peritoneum peritoneum NN 1166 1168 or or CC 1169 1176 derived derive VBN 1177 1181 from from IN 1182 1186 bone bone NN 1187 1193 marrow marrow NN 1193 1194 ) ) ) 1194 1195 . . . 1196 1207 Importantly importantly RB 1207 1208 , , , 1209 1236 methylprednisolone-mediated methylprednisolone-mediated JJ 1237 1248 enhancement enhancement NN 1249 1251 of of IN 1252 1255 the the DT 1256 1262 uptake uptake NN 1263 1265 of of IN 1266 1275 apoptotic apoptotic JJ 1276 1287 neutrophils neutrophil NNS 1288 1291 did do VBD 1292 1295 not not RB 1296 1303 trigger trigger VB 1304 1307 the the DT 1308 1315 release release NN 1316 1318 of of IN 1319 1322 the the DT 1323 1333 chemokines chemokine NNS 1334 1338 IL-8 il-8 NN 1339 1342 and and CC 1343 1351 monocyte monocyte NN 1352 1367 chemoattractant chemoattractant NN 1368 1377 protein-1 protein-1 NN 1377 1378 . . . 1379 1390 Furthermore furthermore RB 1390 1391 , , , 1392 1403 longer-term longer-term JJ 1404 1416 potentiation potentiation NN 1417 1419 by by IN 1420 1438 methylprednisolone methylprednisolone NN 1439 1442 was be VBD 1443 1451 observed observe VBN 1452 1454 in in IN 1455 1463 maturing mature VBG 1464 1469 human human JJ 1470 1486 monocyte-derived monocyte-derived JJ 1487 1488 M M NNP 1489 1492 phi phi NN 1492 1493 , , , 1494 1498 with with IN 1499 1506 greater great JJR 1507 1516 increases increase NNS 1517 1519 in in IN 1520 1525 5-day 5-day JJ 1526 1527 M M NNP 1528 1531 phi phi NN 1532 1538 uptake uptake NN 1539 1541 of of IN 1542 1551 apoptotic apoptotic JJ 1552 1557 cells cell NNS 1558 1563 being be VBG 1564 1572 observed observe VBN 1573 1576 the the DT 1577 1584 earlier early JJR 1585 1600 glucocorticoids glucocorticoid NNS 1601 1605 were be VBD 1606 1611 added add VBN 1612 1618 during during IN 1619 1627 monocyte monocyte NN 1628 1638 maturation maturation NN 1639 1643 into into IN 1644 1645 M M NNP 1646 1649 phi phi NN 1649 1650 . . . 1651 1653 We we PRP 1654 1662 conclude conclude VBP 1663 1667 that that IN 1668 1680 potentiation potentiation NN 1681 1683 of of IN 1684 1697 nonphlogistic nonphlogistic JJ 1698 1707 clearance clearance NN 1708 1710 of of IN 1711 1720 apoptotic apoptotic JJ 1721 1731 leukocytes leukocyte NNS 1732 1734 by by IN 1735 1745 phagocytes phagocyte NNS 1746 1748 is be VBZ 1749 1750 a a DT 1751 1759 hitherto hitherto RB 1760 1772 unrecognized unrecognized JJ 1773 1781 property property NN 1782 1784 of of IN 1785 1800 glucocorticoids glucocorticoid NNS 1801 1805 that that WDT 1806 1809 has have VBZ 1810 1819 potential potential JJ 1820 1832 implications implication NNS 1833 1836 for for IN 1837 1846 therapies therapy NNS 1847 1852 aimed aim VBN 1853 1855 at at IN 1856 1865 promoting promote VBG 1866 1869 the the DT 1870 1880 resolution resolution NN 1881 1883 of of IN 1884 1896 inflammatory inflammatory JJ 1897 1905 diseases disease NNS 1905 1906 . . .